Literature DB >> 29525846

Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study.

Shohei Anno1,2, Yuko Sugioka3, Kentaro Inui4, Masahiro Tada4, Tadashi Okano4, Kenji Mamoto4, Tatsuya Koike5,6,7.   

Abstract

To evaluate work disability and associated factors in patients with rheumatoid arthritis (RA) who participated in the TOMORROW study, a 10-year cohort study in Japan. Subjects in this cross-sectional analysis comprised 191 RA patients and 191 age- and sex-matched non-RA individuals. Work-related outcomes were measured using the Work Productivity and Activity Impairment questionnaire by employment status (full-time worker (FTW), employed ≥ 35 h/week; part-time worker (PTW), < 35 h/week; home worker (HW), non-employed). In addition, we assessed the EuroQol-5 Dimensions (EQ-5D) and Health Assessment Questionnaire (HAQ) to evaluate quality of life and activities of daily living. No significant differences were evident between groups in percentages of participants in each employment status (p = 0.11), percentages of absenteeism (FTW, p = 1.00; PTW, p = 0.29), presenteeism (FTW, p = 0.23; PTW, p = 0.54), overall work impairment (FTW, p = 0.23; PTW, p = 0.73), or percentage of activity impairment (AI) (FTW, p = 0.62; PTW, p = 0.60). In the HW group, percentage of AI was higher in RA patients than that in non-RA patients (p < 0.01). Among RA patients, HW showed lower EQ-5D and higher HAQ than FTW or PTW (p < 0.001 each). Higher disease activity was observed in HW than FTW (p < 0.01). In terms of the effect of biological disease-modifying anti-rheumatic drugs, no significant differences in work-related outcomes, health status, or daily activity were evident between users and non-users. No significant differences in employment status or work impairment were seen between RA and non-RA groups among paid workers. HW with RA showed more impaired daily activity and higher disease activity compared to working RA patients. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry: UMIN000003876 . Registered 1 Jun 2010.

Entities:  

Keywords:  Absenteeism; Disease activity; Overall work impairment; Presenteeism; Rheumatoid arthritis; Work disability

Mesh:

Year:  2018        PMID: 29525846     DOI: 10.1007/s10067-018-4060-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  42 in total

1.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

2.  Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Authors:  Vappu Rantalaiho; Hannu Kautiainen; Markku Korpela; Pekka Hannonen; Oili Kaipiainen-Seppänen; Timo Möttönen; Markku Kauppi; Anna Karjalainen; Kari Laiho; Leena Laasonen; Mikko Hakola; Ritva Peltomaa; Marjatta Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2013-08-01       Impact factor: 19.103

3.  Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

Authors:  Kari Puolakka; Hannu Kautiainen; Timo Möttönen; Pekka Hannonen; Markku Korpela; Markku Hakala; Pentti Järvinen; Jari Ahonen; Sinikka Forsberg; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2005-01

4.  Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.

Authors:  Saralynn Allaire; Frederick Wolfe; Jingbo Niu; Yuqing Zhang; Bin Zhang; Michael LaValley
Journal:  Arthritis Rheum       Date:  2008-08-15

5.  Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.

Authors:  Kari Puolakka; Hannu Kautiainen; Timo Möttönen; Pekka Hannonen; Markku Korpela; Heikki Julkunen; Reijo Luukkainen; Kaisa Vuori; Leena Paimela; Harri Blåfield; Markku Hakala; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2004-01

6.  Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.

Authors:  Wei Zhang; Nick Bansback; Daphne Guh; Xin Li; Bohdan Nosyk; Carlo A Marra; Aslam H Anis
Journal:  J Rheumatol       Date:  2008-08-01       Impact factor: 4.666

7.  Functional disability in rheumatoid arthritis patients compared with a community population in Finland.

Authors:  Tuulikki Sokka; Eswar Krishnan; Arja Häkkinen; Pekka Hannonen
Journal:  Arthritis Rheum       Date:  2003-01

Review 8.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Authors:  Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-03-06       Impact factor: 19.103

Review 9.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Authors:  Josef S Smolen; Ferdinand C Breedveld; Gerd R Burmester; Vivian Bykerk; Maxime Dougados; Paul Emery; Tore K Kvien; M Victoria Navarro-Compán; Susan Oliver; Monika Schoels; Marieke Scholte-Voshaar; Tanja Stamm; Michaela Stoffer; Tsutomu Takeuchi; Daniel Aletaha; Jose Louis Andreu; Martin Aringer; Martin Bergman; Neil Betteridge; Hans Bijlsma; Harald Burkhardt; Mario Cardiel; Bernard Combe; Patrick Durez; Joao Eurico Fonseca; Alan Gibofsky; Juan J Gomez-Reino; Winfried Graninger; Pekka Hannonen; Boulos Haraoui; Marios Kouloumas; Robert Landewe; Emilio Martin-Mola; Peter Nash; Mikkel Ostergaard; Andrew Östör; Pam Richards; Tuulikki Sokka-Isler; Carter Thorne; Athanasios G Tzioufas; Ronald van Vollenhoven; Martinus de Wit; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2015-05-12       Impact factor: 19.103

10.  Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

Authors:  Victoria Bejarano; Mark Quinn; Philip G Conaghan; Richard Reece; Anne-Maree Keenan; David Walker; Andrew Gough; Michael Green; Dennis McGonagle; Ade Adebajo; Stephen Jarrett; Sheelagh Doherty; Lesley Hordon; Richard Melsom; Kristina Unnebrink; Hartmut Kupper; Paul Emery
Journal:  Arthritis Rheum       Date:  2008-10-15
View more
  1 in total

1.  Socioeconomic inequality in patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Nader Salari; Mohsen Kazeminia; Shamarina Shohaimi; Masoud Mohammadi
Journal:  Clin Rheumatol       Date:  2021-06-22       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.